Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 362, Issue 4, Pages 982-987Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2007.08.093
Keywords
spinocerebellar ataxia; protein kinase c gamma; gap junctions; endoplasmic reticulum stress; protein aggregation; caspase-12; PERK; BiP/GRP78; caspase-3; C1B1 synthetic peptide; neuroprotection
Categories
Funding
- NCRR NIH HHS [P20 RR016475] Funding Source: Medline
- NEI NIH HHS [R01 EY013421-06S1, R01 EY013421-03, EY013421, R01 EY013421-02, R01 EY013421-07, R01 EY013421-05, R01 EY013421-04, R01 EY013421, R01 EY013421-01, R01 EY013421-06] Funding Source: Medline
Ask authors/readers for more resources
Mutations in the protein kinase C gamma (PKC gamma) gene cause spinocerebellar ataxia type 14 (SCA14), a heterogeneous neurodegenerative disorder. Synthetic peptides (C1 B1) serve as gap junction inhibitors through activation of PKC gamma control of gap junctions. We investigated the neuroprotective potential of these peptides against SCA14 mutation-induced cell death using neuronal HT22 cells. The C1B1 synthetic peptides completely restored PKC gamma enzyme activity and subsequent control of gap junctions. PKC gamma SCA14 mutant proteins were shown to cause aggregation which initially resulted in endoplasmic reticulum (ER) stress and cell apoptosis as demonstrated by phosphorylation of PERK on Thr981, activation of caspase-12, increases in BiP/GRP78 protein levels, and consequent activation of caspase-3. Pre-incubation with C1B1 peptides completely abolished these SCA14 effects on ER stress and caspase-3 activation, suggesting that C1B1 peptides protect cells from apoptosis through inhibition of gap junctions by restoration of PKC gamma control of gap junctions, which may result in neuroprotection in SCA14. (C) 2007 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available